The CAR T Cells clinical trial involves removing the patients’ cells and modifying them in Penn's Cell and Vaccine Production Facility in Philadelphia. Those cells are then infused the back into the patients following chemotherapy, providing a tumor-attack roadmap for the treatment of other cancers including those of the lung and ovaries and myeloma and melanoma.
The CART19 trial is designed for patients with documented CD19 positive leukemia or lymphoma. These include patients with:
- Acute lymphoblastic leukemia (ALL)
- Chronic lymphocytic leukemia (CLL)
- Follicular lymphoma
- Mantle cell lymphoma
- B cell prolymphocytic leukemia (PLL)
- Diffuse large cell lymphoma
It is important to note that this therapy is very early in testing, and is open to only a small number of participants. Researchers testing any new approaches to cancer treatment must be methodical and meticulous to protect patients and validate findings.
Learn more about the CAR T Cells Trial’s findings or other clinical trials currently enrolling patients at the Abramson Cancer Center or, Oncolink or www.clinicaltrials.gov. Or call 800-474-9892 to find a clinical trial right for you.
Make an appointment with a Penn Medicine blood cancer specialist.
Learn more about the hematological malignancies (blood cancers) program at the Abramson Cancer Center.